PUBLIC COMPANY
save$AVBPArriVent BioPharma, Inc.
$AVBP13.33-1.30%Newtown Square, PA, USupdated 4d ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
5
approvals ytd
2
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 31Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- phase1Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- phase1A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- phase1Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
- phase3Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
🐶 Hiring Signal
News
- Significant stock movers of October: Biohaven climbs, ArriVent divesA fresh FDA review for Biohaven’s embattled ataxia drug lifted the biotech's shares, while a late-stage lung cancer miss battered ArriVent, which failed to rebound even after encouraging early ADC…biospace · 14d ago
- ArriVent sheds nearly half of value on late-stage lung cancer missArriVent BioPharma’s Phase 3 lung cancer trial was clouded by stronger-than-expected data for patients receiving chemotherapy, prompting analysts to pivot focus to a late-stage test of the tyrosine…biospace · 1mo ago
- ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanksArriVent BioPharma, an early adopter of the China licensing model, reported that its lead lung cancer drug failed a Phase 3 trial. Firmonertinib, an EGFR inhibitor, was first approved for lung ...endpoints · 1mo ago
- New Taiho, Cullinan data heats up lung cancer drug battleThe findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.biopharma_dive · 3mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that